Talat Aykut

9PUBLICATIONS
30CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Chemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jun 26, 2026
Prognostic Value of C-Reactive Protein-Albumin-Lymphocyte (CALLY) Index for Survival in Nivolumab-Treated Metastatic Renal Cell Carcinoma.

|May 27, 2026
Prognostic Role of Uric Acid-to-Albumin Ratio in Patients with Metastatic Breast Cancer Treated with CDK4/6 Inhibitors.

|Feb 27, 2026
Prognostic Significance of Albumin-Bilirubin (ALBI) Score in Gastric Cancer Patients Undergoing Curative Resection Followed by Adjuvant Therapy.

Talat Aykut, Oğuzhan Yıldız, Bahattin Engin Kaya

|Jan 28, 2026
Paradoxical Effect of Obesity on Survival Outcomes in Prostate Cancer Patients Receiving Enzalutamide and Abiraterone.

Bahattin Engin Kaya, Mehmet Zahid Koçak, Oğuzhan Yıldız

|Oct 29, 2025
Prognostic Impact of Concomitant Beta-Blocker Use on Survival in EGFR-Mutant Metastatic Non-Small Cell Lung Cancer Patients Treated with Erlotinib.

Oğuzhan Yıldız, Talat Aykut, Bahattin Engin Kaya

|Sep 13, 2025
FOLFIRINOX: The Best Adjuvant Treatment for Ampullary Adenocarcinoma? A Multicenter Study by the Turkish Oncology Group (TOG).

Ali Kalem, Tulay Kus, Taha Koray Sahin

Pageof 2

Frequent Collaborators

8 joint publications

Murat Araz

6 joint publications

Mehmet Artaç

6 joint publications

Oğuzhan Yıldız

5 joint publications

Mehmet Zahid Koçak